SF3B1 and myelodysplastic syndrome: Although we observed decreases in peripheral blood and bone marrow in the SF3B1 mutant cells with the combination of eltanexor and A1331852, given the weight loss and toxicity seen in these mice, the combination of eltanexor and venetoclax appeared to be a more promising combination for future development in clinical trials for patients with SF3B1 mutant MDS.